SOMATOTROPIC RESEARCH

CJC-1295 Without DAC: GHRH Analogue Research Overview

Velox Peptides Research Team·Published May 2026·6 min read
Sequence
Modified GHRH(1-29)
Peptide Class
GHRH analogue
Target
GHRH receptor
HPLC Purity
≥99.1% (batch-verified)
For in vitro research use only. CJC-1295 without DAC is supplied solely as a research reagent for in vitro use and is not for human or veterinary consumption.

What is CJC-1295 without DAC?

CJC-1295 without DAC — also referred to in the literature as Modified GRF(1-29) — is a synthetic analogue of the first 29 amino acids of growth-hormone-releasing hormone (GHRH(1-29)), the bioactive fragment of GHRH. It carries four amino-acid substitutions that increase its stability against the enzyme DPP-IV, extending its functional half-life relative to native GHRH.

The phrase “without DAC” distinguishes it from the DAC-conjugated version. DAC (Drug Affinity Complex) is a chemical group that binds albumin to dramatically extend half-life to days; the version without DAC is shorter-acting, which makes it a research tool for studying GHRH-receptor activation with a more physiological, pulsatile profile.

GHRH-receptor activation and GH pulse research

Receptor mechanism. Like Tesamorelin, CJC-1295 without DAC binds the GHRH receptor on pituitary somatotroph cells, stimulating the release of the body’s own growth hormone. It acts upstream of GH rather than supplying GH directly.

Half-life and pulse amplitude. The key research distinction between the DAC and non-DAC forms is duration of action. The non-DAC form’s shorter half-life is studied for its association with discrete GH pulses that more closely mimic natural pulsatile secretion, whereas the DAC form sustains elevated GHRH-receptor activity over a longer window. This makes the two forms complementary tools for studying how the pattern of GHRH-receptor stimulation affects downstream GH dynamics in animal models.

CJC-1295 and Tesamorelin

CJC-1295 without DAC and Tesamorelin are both GHRH analogues acting on the same receptor, giving researchers two related tools that differ in sequence and half-life. They are commonly studied together in the somatotropic research category. See the Tesamorelin research overview for a comparison of GHRH-analogue mechanisms.

Velox Peptides supply information

Velox Peptides supplies CJC-1295 without DAC as a lyophilised powder at ≥99.1% HPLC-verified purity with a batch certificate of analysis available on request. For reconstitution, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Teichman SL et al. “Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH.” Journal of Clinical Endocrinology & Metabolism, 2006. (Human clinical data — mechanistic context only.)

Summaries are paraphrased from the peer-reviewed literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What does “without DAC” mean?
DAC (Drug Affinity Complex) is a chemical group that binds albumin to extend half-life to days. “Without DAC” is the shorter-acting form, studied for a more pulsatile GHRH-receptor activation profile.
How does CJC-1295 differ from Tesamorelin?
Both are GHRH analogues acting on the same receptor, but they differ in sequence and half-life, giving researchers two related tools for comparative somatotropic studies.
What purity is Velox Peptides CJC-1295?
CJC-1295 without DAC is HPLC-verified at a minimum of 99.1% purity, with batch documentation available on request.
Is CJC-1295 legal to buy in the UK?
Yes — for in vitro research purposes. It is not a licensed medicine and not for human use. Velox Peptides supplies it solely as a research reagent.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.